What the FDA labels say about taking them together
Clarithromycin and lomitapide
Clarithromycin's FDA label of April 9, 2026 names lomitapide in its contraindications section, and lomitapide's label names clarithromycin too. The lomitapide label: “… a drug-drug interaction between JUXTAPID and the strong CYP3A4 inhibitor clarithromycin.”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the lomitapide FDA label on DailyMed (effective March 30, 2026, Chiesi USA, Inc.).
What does the clarithromycin label say about lomitapide?
Clarithromycin label, contraindicationsCONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride and pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone
Clarithromycin label, drug interactionsLomitapide Lovastatin Simvastatin; Contraindicated; Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [See Contraindications and Warnings and Precautions ] Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions ]
Clarithromycin label, warnings and precautionsThese include colchicine toxicity with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes ) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine).
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the lomitapide label say about clarithromycin?
Lomitapide label, warnings and precautionsAmong the 19 patients who subsequently enrolled in the adult HoFH extension trial, one discontinued because of increased transaminases that persisted despite several dose reductions, and one temporarily discontinued because of markedly elevated transaminases (ALT 24 times ULN, AST 13 times ULN) that had several possible causes, including a drug-drug interaction between JUXTAPID and the strong CYP3A4 inhibitor clarithromycin [see Drug Interactions (7.1) ].
Source: FDA drug label (Juxtapid), Chiesi USA, Inc., effective March 30, 2026 (SPL set 61a0be9d-ee58-43e0-b5cb-141011835081), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Lomitapide | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | High cholesterol |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once